Western Europe remains at the forefront of evidence-based harm reduction and treatment interventions. The majority of the countries in the region have adopted a health-based strategy towards drug use (including decriminalisation of possession for personal use), and are moving towards more proportionate sentences for drug offences.
Prisons are in crisis with record levels of suicides, violence and self-harm. Spurred on by synthetic cannabinoids, 8% of men in prison in England and Wales report developing a drug problem since they have been in prison. In prisons with the worst regimes this is as high as 16%.
The International Conference on Medical Cannabis, held at the EU Parliament, aimed share knowledge about the state of legislation around the world today, and to educate regulators present about the importance of building legal, regulated cannabis markets in Europe.
Paris, France Palais des Congrès, 2 Place de la Porte Maillot, Paris
the program will serve as platform to showcase the current state of the HIV basic, clinical, social and implementation science fields and will offer interactive workshops, networking opportunities with leading researchers, and forums to share best practices and more.
The EMCDDA publishes a report providing an update on infectious diseases related to injecting drug use in Europe, it covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area.
The Civil Society Forum on Drugs (CSF), an expert group of the European Commission held its annual plenary meeting in Brussels last week. The Forum has become an important voice, but it needs more inclusion and funding from EU institutions.
As NPS have entered the markets at an unprecedented rate, legislation has been unable to keep pace. This report for policymakers and legal practioners, from the EMCDDA and Eurojust, aims to outline the challenges and paths forward in NPS regulation.